9 results about "Multiple administration" patented technology

Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.

The invention relates to the technical field of gynecological disease adjuvant therapy instruments, in particular to a vagina drug delivery device which comprises a tube body, a drug storage bag, a threaded push rod, an injection tube, a rotating assembly, a protective cap and a liquid storage bag, a fixing ring is installed at one end of the tube body, and internal threads are arranged on the inner wall of the fixing ring; according to the vagina drug delivery device, through the scale strip on the outer wall of the first threaded sleeve, a user can intuitively set the needed drug delivery dosage, rotate the rotating cylinder anticlockwise to enable the first threaded sleeve to stretch out, observe the scale strip to be adjusted to the preset position, and the user can conveniently and rapidly deliver the drug delivery dosage. The liquid storage bag is filled with the medical lubricant, the medical lubricant is adhered to the outer wall of the injection tube through the sponge ring, friction and discomfort during insertion are reduced, and the acceptability and compliance of a patient are improved, especially under the condition that multiple times of administration are needed, through the design, the dosage of the liquid storage bag is ensured to be accurate, and the liquid storage bag is filled with the medical lubricant and is adhered to the outer wall of the injection tube through the sponge ring.

The utility model relates to the technical field of glycerine enema, in particular to glycerine enema capable of being dosed repeatedly, which comprises a liquid storage ball, an anti-leakage mechanism arranged above the liquid storage ball and a complete extrusion mechanism arranged above the liquid storage ball, the anti-leakage mechanism comprises a connecting pipe, the connecting pipe is fixedly connected to the upper end of the liquid storage ball, and the connecting pipe is connected with the complete extrusion mechanism. The connecting pipe is rotationally arranged in the rotating sleeve, a first through groove is formed in the connecting pipe, a connecting ring is fixedly connected to the upper end of the rotating sleeve, a fixing plate is fixedly connected to the inner wall of the connecting ring, a second through groove is formed in the fixing plate, and the area of the second through groove is the same as that of the first through groove; the upper end of the connecting ring is fixedly connected with an extrusion pipe, and a lengthening pipe is installed at the upper end of the extrusion pipe. According to the enema capable of dosing for multiple times, the enema can be conveniently dosed, the dosed enema can be sealed subsequently, pollution and waste caused by automatic extrusion of leaked enema are avoided, and the practicability and the closeness of the enema are improved.

The present invention discloses a crystalline form of a compound, as well as its preparation and use. The compound has the structure shown in Formula I. The crystalline form has relatively good solid-state stability and flowability, relatively low hygroscopicity, and relatively good solubility, making it advantageous for the preparation and storage of pharmaceutical formulations. Furthermore, the crystalline form has excellent pharmacokinetic properties, relatively excellent safety during repeated administration, and can be administered via multiple administration routes (e.g., injection, oral administration). It is available in a wide range of formulations, and has particularly high oral bioavailability, making it highly valuable for practical applications. The crystalline form can be used as a JAK inhibitor to develop drugs for the prevention and / or treatment of inflammatory diseases, tumors, autoimmune diseases, and allergic diseases in humans and / or animals. [Formula 1] JPEG2025542332000054.jpg45170

Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and / or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and / or administering the cells expressing the second receptor to a subject having received the first administration. The methods can provide various advantages, such as improved efficacy in the context an immune response in the subject against the first or prior receptor and / or in the context of antigen loss, downregulation, or modification, following a first or prior administration.

This application relates to the field of biomedical technology, proposing a compound that targets and degrades RALBP1 protein, its preparation, and its application. The compound is the compound shown in formula (I), or its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs. The compound of this application belongs to the PROTAC drug category, which can target small molecule conjugates of RALBP1, thereby inducing RALBP1 degradation and achieving effective prevention or treatment of acute myeloid leukemia. Simultaneously, the compound of this application can be used in oral formulations; through structural optimization, it balances drug activity and oral convenience. Single or multiple administrations can produce significant tumor-suppressive effects, demonstrating broad application prospects. (I)

To prevent a patient from forgetting to take a medicine, and warn the patient to recognize a particularly important administration timing among multiple administration timings.SOLUTION: An information processing device includes at least one processor. The at least one processor associates, based on input administration information for a plurality of medicines, an administration timing that meets a predefined condition among a plurality of administration timings which are timings of taking at least one of the plurality of medicines, with warning information which is information for warning the patient to recognize the medicine to be taken among the plurality of medicines at the administration timing. The at least one processor then outputs the associated warning information and the administration timing to an output device.SELECTED DRAWING: Figure 6

Described are viral vectors, compositions, kits, and methods or using the vectors, compositions, kits to modulate immune response in a subject. The viral vectors include therapeutic recombinant adeno-associated viruses (rAAVs) and tolerance inducing gene therapy vectors. The therapeutic rAAVs and tolerance inducing gene therapy vectors can be used to deliver one or more therapeutic nucleic acids to the subject. The tolerance inducing gene therapy vectors induce immune-specific tolerance to the therapeutic rAAVs to improve efficacy of the therapeutic rAAVs and allow for multiple administrations of the therapeutic rAAVs with little or no associated immune response to the therapeutic rAAVs. The therapeutic rAAVs can be used to administer a therapeutic effect to the subject.

This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered multiple times to an organism requiring tumor treatment, at a radioactive dose that avoids dose-limiting toxicity, as determined on the basis of hematological parameters. The multiple administration preferably consists of intermittent administration at time intervals allowing the hematological parameters to return to a normal range.